LVTX
LAVA Therapeutics Nv : Leerink Partners Cuts to Market Perform From Outperform; Cuts Target Price to $2 From $11
时间：2024-12-12 20:06:23 市场： 美股 综合
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension Into 2027
时间：2024-12-10 20:30:01 市场： 美股 综合